Kel­ly Mar­tin once again finds him­self at the helm of a biotech, sail­ing in chop­py seas

Kel­ly Mar­tin is once again run­ning a biotech com­pa­ny — on­ly this time it’s just a tem­po­rary gig un­til a more per­ma­nent re­place­ment can be found to run No­van $NOVN, a port­fo­lio com­pa­ny of his at Ma­lin that ran in­to some pro­found trou­ble re­cent­ly.

Mar­tin, the for­mer chief ex­ec­u­tive at Elan, switched to in­ter­im CEO from his post on the board at No­van, which he ac­quired as his ven­ture group Ma­lin jumped in as a big in­vestor of the Uni­ver­si­ty of North Car­oli­na spin­out. He was tapped as the board de­cid­ed to shake things up, lay­ing off around a dozen staffers and fo­cus­ing the found­ing CEO Nate Stasko on his role as chief sci­en­tif­ic of­fi­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.